Trial reportBritish journal of clinical pharmacology2026
Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.
Trial report in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.British journal of clinical pharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn the AEGEAN study, perioperative durvalumab plus platinum-based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non-small-cell lung cancer (NSCLC) demonstrated a favourable benefit-risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure-response (ER) relationships of durvalumab in patients with resectable NSCLC.
methodsThe durvalumab PopPK model was updated by integrating PK data from the AEGEAN study. Individual exposure metrics were derived from empirical Bayes estimates for ER analyses relating to safety (adverse events [AEs]) and efficacy (pathological complete response [pCR] and event-free survival [EFS]).
resultsA two-compartment model with a time-dependent clearance adequately characterized durvalumab PK data. The typical parameter estimates clearance, central and peripheral volume of distribution were 0.285 L/day (relative standard error: 1.68%), 3.42 L (0.962%) and 2.30 L (2.09%), respectively. All identified covariates caused ≤21% of change on durvalumab PK parameters, indicating no meaningful impact on durvalumab exposure. At the plateaued dose level of durvalumab 1500 mg, a flat relationship was observed between durvalumab PK exposure and EFS, confirmed by Cox proportional hazards analysis, and pCR, confirmed by logistic regression analysis. Logistic regression analysis indicated that no clinically relevant relationships were observed between durvalumab PK exposure and safety endpoints, including grade ≥3 treatment-related AEs, grade ≥3 treatment-related AEs of special interest, and AEs leading to treatment discontinuation.
conclusionsThese results support the novel perioperative durvalumab regimen for patients with resectable NSCLC from the AEGEAN study, and no dose adjustment is necessary based on the PopPK and ER analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.